By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...
Nearly half a million people are diagnosed and treated for Lyme disease in the U.S. every year, and Pennsylvania is a hot bed ...
In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot because of a lack of ...
Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...
A new vaccine to prevent Lyme disease in humans may soon be available. Pfizer said it's planning to seek regulatory approval.
13d
Pfizer to seek FDA approval for Lyme vaccine as CT report shows ticks are more abundant than ever
The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of ...
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though ...
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results